You searched for Acalabrutinib - Page 3 of 25

ASH 2022: Dr. Matthew Davids on the Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL / SLL)

February 6, 2023

Our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute. They discussed the results of a new study looking at whether combining the anti-CD20 monoclonal antibody obinutuzumab with the BTK inhibitor acalabrutinib provided any additional survival benefit.

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

January 24, 2023

In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical trial to compare acalabrutinib and ibrutinib head-to-head.

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)

January 6, 2023

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with none of the more serious abnormal ventricular heart irregularities seen.

Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)

November 18, 2022

The combination of obinutuzumab (Gazyva), acalabrutinib (Calquence), and venetoclax (Venclexta) failed to meet the pre-specified rate of undetectable measurable or minimal residual disease (uMRD) following optimal debulking with bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

ASH 2021: MAJIC – A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

October 12, 2022

In summary, the results of MAJIC will help to inform the selection of time-limited doublet therapy approaches for patients with CLL / SLL and help define the duration of venetoclax in combination with either acalabrutinib or obinutuzumab.

ASH 2021: Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

September 13, 2022

Acalabrutinib plus high-frequency, low-dose subcutaneous rituximab is tolerable and effective. In addition, because it can be administered at home, it is more convenient and can decrease patient infection risk during pandemics. However, while it does control disease, it does not lead to undetectable measurable residual disease (uMRD).

ASH 2021: Dr. John Seymour on Side Effects of Acalabrutinib vs. Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

September 1, 2022

We discuss updated safety results from the ELEVATE R/R study, which is the first study comparing acalabrutinib with ibrutinib head-to-head in patients with relapsed/refractory CLL.

ASCO 2022: Acalabrutinib Versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): ASCEND Results at 4 Years of Follow-Up

August 25, 2022

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial.
This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.

AstraZeneca: Newly Approved Acalabrutinib Tablet Formulation for Patients with CLL / SLL Allows Use of Acid-Reducing Agents

August 19, 2022

The FDA has signed off on a new tablet formulation for acalabrutinib (Calquence) for patients with CLL / SLL, according to a news release from drugmaker AstraZeneca. It is now possible to take acalabrutinib along with stomach acid-reducing agents.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Acalabrutinib – Page 3

ASH 2022: Dr. Matthew Davids on the Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL / SLL)

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)

Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)

ASH 2021: MAJIC – A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

ASH 2021: Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

ASH 2021: Dr. John Seymour on Side Effects of Acalabrutinib vs. Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

ASCO 2022: Acalabrutinib Versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): ASCEND Results at 4 Years of Follow-Up

AstraZeneca: Newly Approved Acalabrutinib Tablet Formulation for Patients with CLL / SLL Allows Use of Acid-Reducing Agents

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT